OverviewSuggest Edit

Zymergen is a company that researches, develops and manufactures microbes for industrial application. It develops molecules for biomedical coatings and adhesives that can be used as surgical glues either inside the body or on the skin to close a wound or to protect against infection. The company also integrates artificial intelligence algorithms and robotic genomic to search the microbial genome, discover new materials, commercialize new products and improve existing bio-manufactured products.

TypePrivate
Founded2013
HQEmeryville, CA, US
Websitezymergen.com
Employee Ratings3.2
Overall CultureD-

Latest Updates

Employees (est.) (Sept 2021)833
Job Openings5
Revenue (FY, 2020)$13.3 M(-13%)
Share Price (Sept 2021)$13.8(+4%)
Cybersecurity ratingAMore

Key People/Management at Zymergen

Josh Hoffman

Josh Hoffman

Chief Executive Officer and Co-Founder, Director
Judy Gilbert

Judy Gilbert

Chief People Officer
Jack Gold

Jack Gold

Chief Marketing Officer
Mina Kim

Mina Kim

Chief Legal Officer
Aaron Kimball

Aaron Kimball

Chief Technology Officer
Zach Serber

Zach Serber

Chief Science Officer and Co-Founder
Show more

Zymergen Office Locations

Zymergen has offices in Emeryville, Boise, Seattle and 千代田区
Emeryville, CA, US (HQ)
5980 Horton St #105
Boise, ID, US
12426 W Explorer Dr #250
Seattle, WA, US
1624 4th Ave #300
千代田区, JP
4F Otemachi First Square 1-5-1 Otemachi Chiyoda-ku
Show all (5)

Zymergen Financials and Metrics

Summary Metrics

Founding Date

2013

Zymergen total Funding

$876.1 m

Zymergen latest funding size

$300 m

Time since last funding

a year ago

Zymergen investors

Zymergen's latest funding round in September 2020 was reported to be $300 m. In total, Zymergen has raised $876.1 m
Show all financial metrics

Zymergen Revenue

Embed Graph
View revenue for all periods
Zymergen's revenue was reported to be $13.28 m in FY, 2020 which is a 13.8% decrease from the previous period.
USD

Revenue (FY, 2020)

13.3m

Revenue growth (FY, 2019 - FY, 2020), %

(13.8%)

Gross profit (FY, 2020)

(71.5m)

Gross profit margin (FY, 2020), %

(538.5%)

Net income (FY, 2020)

(262.2m)

EBIT (FY, 2020)

241.1m

Cash (31-Dec-2020)

210.2m
USDFY, 2019FY, 2020

Revenue

15.4m13.3m

Revenue growth, %

(14%)

Cost of goods sold

102.6m84.8m

Gross profit

(87.2m)(71.5m)
USDFY, 2019FY, 2020

Cash

143.6m210.2m

Accounts Receivable

2.4m2.5m

Prepaid Expenses

5.4m7.0m

Inventories

2.2m5.0m
USDFY, 2019FY, 2020

Net Income

(236.8m)(262.2m)

Depreciation and Amortization

15.2m18.7m

Inventories

(907.0k)(2.7m)

Accounts Payable

344.0k(4.4m)
USDFY, 2019

Revenue/Employee

22.1k

Debt/Equity

-0.2 x

Debt/Assets

0.4 x

Financial Leverage

-0.5 x
Show all financial metrics

Zymergen Operating Metrics

FY, 2020

Action Areas

4

Facility Space, sq. ft.

262 k

Patent Applications (US)

500

Patents Pending (US)

322
Show all operating metrics

Zymergen Acquisitions / Subsidiaries

Company NameDateDeal Size
enEvolvMarch 19, 2020
Radiant GenomicsJanuary 08, 2018

Zymergen Revenue Breakdown

Embed Graph

Zymergen revenue breakdown by geographic segment: 45.9% from United States of America, 35.7% from Asia and 18.4% from Europe

Human Capital Metrics

Source: github.com
Embed Graph
Show all human capital metrics

Zymergen Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Zymergen Online and Social Media Presence

Embed Graph

Zymergen Company Culture

  • Overall Culture

    D-

    56/100

  • CEO Rating

    D-

    56/100

  • Compensation

    B

    74/100

Learn more on Comparably

Zymergen News and Updates

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zymergen, Annovis Bio, and Cassava Sciences and Encourages Investors to Contact the Firm

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Zymergen Inc. (NASDAQ: ZY), Annovis Bio, Inc. (NYSE: ANVS), and Cassava Sciences,…

ZY CLASS ACTION LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Zymergen, Inc.

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securiti…

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zymergen Inc. (ZY)

BENSALEM, Pa., Sept. 20, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming October 4, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased or otherwise acquired Zymergen Inc. ("Zymergen" or the "Company")...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Zymergen (ZY) Investors of Securities Class Action, Encourages Investors with Losses to Contact Firm’s Attorneys Now

SAN FRANCISCO, Sept. 18, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Zymergen Inc. (NASDAQ: ZY) investors with significant losses to submit your losses now.   

ZY BREAKING ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Zymergen Inc. Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ZY

NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zymergen Inc. (NASDAQ: ZY) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Oatly, Zymergen, Live Ventures, and SelectQuote and Encourages Investors to Contact the Firm

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Oatly Group AB (NASDAQ: OTLY), Zymergen Inc. (NASDAQ: ZY), Live Ventures Incorpor…
Show more

Zymergen Blogs

The brave new world of protein structures and biofacturing

DeepMind has given us the 3-D structures of all human proteins. What does it mean for biofacturing? Here’s our take. The post The brave new world of protein structures and biofacturing appeared first on Zymergen.

Does a billionaire space race really help humankind?

A handful of tourists are taking joy rides to space, but humanity’s true prospects for thriving on- and off-planet depend on unlocking the microbial factories all around us. The post Does a billionaire space race really help humankind? appeared first on Zymergen.

The science of The Tomorrow War: The good, the bad, and the funny

When Hollywood tries its hand at biofacturing, sometimes science truth is better than science fiction The post The science of The Tomorrow War: The good, the bad, and the funny appeared first on Zymergen.

Coding for microbes: A day in the life of a software engineer at Zymergen

A veteran of industry giants Ford and Apple, Aindrea Campbell’s manufacturing know-how will help bring biofacturing into the mainstream. The post Coding for microbes: A day in the life of a software engineer at Zymergen appeared first on Zymergen.

The science of biofacturing: Josh Hoffman on This Week in Startups

CEO Josh Hoffman talks synthetic biology, biofacturing, and what’s next for Zymergen with This Week in Startups podcast host Jason Calacanis. The post The science of biofacturing: Josh Hoffman on This Week in Startups appeared first on Zymergen.

Beyond the t-test: Using Bayesian modeling to separate signal from noise

A data science approach to finding commercially relevant titer improvements in fermentation The post Beyond the t-test: Using Bayesian modeling to separate signal from noise appeared first on Zymergen.
Show more

Zymergen Frequently Asked Questions

  • When was Zymergen founded?

    Zymergen was founded in 2013.

  • Who are Zymergen key executives?

    Zymergen's key executives are Josh Hoffman, Judy Gilbert and Jack Gold.

  • How many employees does Zymergen have?

    Zymergen has 833 employees.

  • What is Zymergen revenue?

    Latest Zymergen annual revenue is $13.3 m.

  • What is Zymergen revenue per employee?

    Latest Zymergen revenue per employee is $15.9 k.

  • Who are Zymergen competitors?

    Competitors of Zymergen include Biodesix, Ischemia Care and Scailyte.

  • Where is Zymergen headquarters?

    Zymergen headquarters is located at 5980 Horton St #105, Emeryville.

  • Where are Zymergen offices?

    Zymergen has offices in Emeryville, Boise, Seattle and 千代田区.

  • How many offices does Zymergen have?

    Zymergen has 5 offices.